Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | METAP2 | P50579 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.73 |
| ▸ | ATM | Q13315 | 1/20 | 0.73 |
| ▸ | CCKBR | P32239 | 10/20 | 0.72 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | CCKAR | P32238 | 4/20 | 0.63 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.56 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.56 |
| ▸ | CASP6 | P55212 | 1/20 | 0.56 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3741036 | 0.91 | MEN1 (0.84) | MEN1METAP2KMT2AL3MBTL1ATM | |
| SCHEMBL3745368 | 0.87 | MEN1 (0.77) | MEN1METAP2KMT2AL3MBTL1ATM | |
| SCHEMBL7213043 | 0.86 | MEN1 (0.76) | MEN1METAP2KMT2AL3MBTL1ATM | |
| SCHEMBL3899468 | 0.85 | L3MBTL1 (1.00) | MEN1METAP2KMT2AL3MBTL1ATM | |
| SCHEMBL13792850 | 0.84 | CCKBR (1.00) | MEN1METAP2KMT2ACCKBR | |
| SCHEMBL3900101 | 0.83 | L3MBTL1 (0.75) | MEN1METAP2KMT2AL3MBTL1ATM | |
| SCHEMBL3749920 | 0.83 | POLB (0.72) | MEN1METAP2KMT2AL3MBTL1ATM | |
| SCHEMBL3745619 | 0.82 | MEN1 (0.69) | MEN1METAP2KMT2AL3MBTL1ATM | |
| SCHEMBL21857833 | 0.81 | L3MBTL1 (0.82) | MEN1METAP2KMT2AL3MBTL1ATM | |
| SCHEMBL3746034 | 0.80 | CCKBR (0.74) | L3MBTL1ATMCCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010290-A1 | Methods of Treating an Overweight or Obese Subject | ZAFGEN, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20120010290-A1 | Methods of Treating an Overweight or Obese Subject | ZAFGEN, INC. | 2012-01-12 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010290-A1 | Methods of Treating an Overweight or Obese Subject | METAP2, METAP1, ACER2 | MEN1 1391/4885METAP2 1/4885KMT2A 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.